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Plasminogen activator inhibitor-1 detaches cells from 
extracellular matrices by inactivating integrins
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The Scripps Research Institute, Department of Cell Biology, Division of Vascular Biology, 10550 N. Torrey Pines Road, VB-3, 
La Jolla, CA 92037
 
he binding of urokinase plaminogen activator (uPA)
to its cell surface receptor (uPAR; CD87) promotes
cell adhesion by increasing the afﬁnity of the receptor
for both vitronectin (VN) and integrins. We provide evidence
that plasminogen activator inhibitor (PAI)-1 can detach
cells by disrupting uPAR–VN and integrin–VN interactions
and that it does so by binding to the uPA present in uPA–
uPAR–integrin complexes on the cell surface. The detached
cells cannot reattach to VN unless their surface integrins are
ﬁrst activated by treatment with MnCl
 
2
 
. Immunoprecipitation
and subcellular fractionation experiments reveal that PAI-1
treatment triggers deactivation and disengagement of uPA–
uPAR–integrin complexes and their endocytic clearance by
T
 
the low density lipoprotein receptor–related protein. Transfec-
tion experiments demonstrate that efﬁcient cell detachment
by PAI-1 requires an excess of matrix-engaged uPA–uPAR–
integrin  complexes over free engaged integrins and that
changes in this ratio alter the efﬁcacy of PAI-1. Together, these
results suggest a VN-independent, uPA–uPAR-dependent
mechanism by which PAI-1 induces cell detachment. This
pathway may represent a general mechanism, since PAI-1
also can detach cells from ﬁbronectin and type-1 collagen.
This novel “deadhesive” activity of PAI-1 toward a variety of
cells growing on different extracellular matrices may begin to
explain why high PAI-1 levels often are associated with a poor
prognosis in human metastatic disease.
 
Introduction
 
Plasminogen activator inhibitor (PAI)*-1 is a member of
the serine proteinase inhibitor (SERPIN) family and is the
primary physiological inhibitor of both tissue-type plasminogen
activator and urokinase-type plasminogen activator (uPA;
Andreasen et al., 2000). It is a trace protein in plasma and
circulates in complex with the adhesive glycoprotein vitronectin
(VN) (van Meijer and Pannekoek, 1995; Loskutoff et al.,
1999). The binding of PAI-1 to VN stabilizes the inhibitor
in its active conformation, and this binding is reversed when
the inhibitor forms complexes with tissue-type plasminogen
activator or uPA.
Activation of pro-uPA frequently occurs when it binds to
uPA receptor (uPAR; CD87) on cells (Kjoller, 2002). Active
uPA on the cell surface can be inhibited by PAI-1 (Cubellis
et al., 1989), and the resulting inactive PAI-1–uPA–uPAR
complexes are rapidly internalized by the low density lipo-
protein (LDL) receptor-related protein (LRP) (Nykjær et al.,
1997; Czekay et al., 2001). Thus, PAI-1 initiates an LRP-
dependent decrease in cell surface uPAR. Interestingly,
uPAR is elevated on the surface of LRP-deficient cells, and
this increase correlates with increased cell mobility (Webb et
al., 2001). The binding of uPA to uPAR stimulates intracellular
signaling (Ossowski and Aguirre-Ghiso, 2000; Kjoller, 2002)
and also induces conformational changes in uPAR (Mondino
et al., 1999; Wei et al., 2001) which increase its affinity for
VN and promote its interaction with a variety of integrins
(Chapman and Wei, 2001; Tarui et al., 2001; Kjoller,
2002). uPAR ligation also can activate certain integrins and
growth factor receptors (Liu et al., 2002).
VN is relatively unique among adhesive proteins not only
because PAI-1 binds to it with high affinity and specificity
but also because cells can attach to it through integrins,
uPAR, or both (Waltz et al., 1997; Deng et al., 2001). The
high affinity binding sites for both PAI-1 and uPAR reside
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in two overlapping but distinct regions of the NH
 
2
 
-termi-
nal somatomedin B (SMB) domain of VN (Okumura et al.,
2002) and are immediately adjacent to the single RGD se-
quence in the molecule. The affinity of PAI-1 for the SMB
domain is much higher than the affinity of uPAR for this
domain (Deng et al., 1996). Thus, PAI-1 can competitively
inhibit the uPAR-dependent attachment of cells to VN
(Deng et al., 1996; Waltz et al., 1997; Deng et al., 2001).
Binding of PAI-1 to SMB also inhibits integrin-mediated
cell adhesion, presumably by sterically blocking the adja-
cent RGD site (Stefansson and Lawrence, 1996; Okumura
et al., 2002). Cells which attach to VN through uPAR can
be detached by PAI-1 (Deng et al., 1996). Whether PAI-1
also can detach cells bound to VN (or other matrices)
through integrins is largely unknown (Germer et al., 1998;
Deng et al., 2001).
In this report, the deadhesive effects of PAI-1 on cells at-
tached to VN via integrins are investigated in detail. Unex-
pectedly, the deadhesive activity of PAI-1 does not appear to
require its interaction with VN. However, there is an abso-
lute requirement for its binding to the uPA present in uPA–
uPAR
 
–
 
integrin complexes on the cell surface. Interestingly,
PAI-1 also detaches cells from fibronectin (FN) and type I
collagen by a similar uPA/uPAR-dependent mechanism.
These observations suggest that cell detachment by PAI-1
may represent a general mechanism for the release of cells
from the extracellular matrix. Thus, PAI-1 should be added
to the list of known deadhesion molecules (e.g., thrombo-
spondin [Murphy-Ullrich, 2001]).
 
Results
 
Detachment of cells from VN by PAI-1
 
Cells can attach to VN through uPAR, integrins, or both.
Since uPAR-mediated cell attachment to VN can be re-
versed by PAI-1 and since PAI-1 also blocks the RGD
sequence in VN, it is possible that excess PAI-1 may com-
petitively displace both uPAR and integrins from their asso-
ciation with VN, thus detaching the cells. According to this
idea, cell detachment results from the binding of PAI-1 to
VN. To test this hypothesis, we examined the behavior of
HT-1080 cells, since they attach to VN via both uPAR and
integrins (Deng et al., 2001). The cells were first acid
treated to remove endogenous uPA from uPAR, thus mak-
ing available a more consistent pool of surface uPAR (Cu-
bellis et al., 1989; Czekay et al., 2001). Little or no cell de-
tachment was observed when the cells were incubated with
uPA or PAI-1 alone compared with the untreated control
cells (Fig. 1 A). However, if the cells were preincubated
with exogenous uPA the subsequent addition of PAI-1 now
detached 
 
 
 
65% of the cells. A similar effect was observed
when the cells were subjected to sequential incubation with
uPA and the PAI-1 mutant which binds to uPA but not to
VN (i.e., PAI-1
 
[P
 
 
 
V
 
 
 
]
 
). However, little detachment was ob-
served using the PAI-1 mutant which does not bind to uPA
(i.e., PAI-1
 
[P
 
 
 
V
 
 
 
]
 
). Thus, cell detachment by PAI-1 seems
to be dependent on the interaction of PAI-1 with uPA and
not with VN. Interestingly, when the cells were incubated
with the non–uPA-binding PAI-1 variant (i.e., PAI-1
 
[P
 
 
 
V
 
 
 
]
 
)
in the presence of RGD peptide (but not the RGE peptide;
unpublished data), the majority of the cells were again de-
tached (Fig. 1 A). The presence of RGD peptide alone had
no effect on cell detachment. Thus, disruption of VN–inte-
grin interactions by the RGD peptide allowed the VN-
binding variant of PAI-1 to detach the cells, presumably be-
cause the cells were now bound to VN only through uPAR
(Deng et al., 2001).
Two experiments were performed to further investigate
the uPA dependency of cell detachment by PAI-1. In the
first, HT-1080 cells were incubated with the amino termi-
nal fragment (ATF) of uPA instead of with uPA itself. Al-
though the ATF binds to uPAR (Ploug et al., 1998), it
Figure 1. Effect of PAI-1 on cell detachment from VN. Microtiter 
wells were coated with VN (A) or VN40–459 (B) and then blocked by 
incubation with BSA for 2 h as indicated in Materials and methods. 
HT-1080 cells were seeded onto the coated wells in serum-free 
medium for 1.5 h, acid washed, and then incubated as indicated 
with either uPA, PAI-1, RGD, or ATF. In some experiments, the cells 
were incubated with uPA or ATF followed by the addition of PAI-1 
or the indicated PAI-1 variants. In other experiments, the cells were 
incubated with PAI-1[P V ] in the presence of RGD peptide. After 
incubation, the wells were vigorously agitated, the floating cells 
were removed by washing, and the number of remaining attached 
cells was determined. Each column is expressed as a percentage of 
the control (acid washed only; 100%)   SD.T
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lacks the catalytic domain of uPA, and thus does not inter-
act with PAI-1. The addition of PAI-1 to the ATF-pre-
treated cells did not lead to cell detachment (Fig. 1 A).
Thus, detachment of HT-1080 cells by PAI-1 depends on
the presence of active uPA bound to uPAR.
In the second experiment, the effect of PAI-1 on cell de-
tachment from VN
 
40–459
 
 was examined. This variant of VN
does not interact with PAI-1 because it lacks the SMB do-
main (i.e., the uPAR and PAI-1 binding sites). However, it
still contains the RGD site necessary for integrin-mediated
attachment. As expected, PAI-1 alone had no effect on cell
detachment (Fig. 1 B). However, if the cells were first prein-
cubated with uPA and then PAI-1 (or the PAI-1 variant
which binds uPA but not VN, i.e., PAI-1
 
[P
 
 
 
V
 
 
 
]
 
) was added,
the majority of the cells were detached. Again, the VN-bind-
ing variant that does not bind to uPA (i.e., PAI-1
 
[P
 
 
 
V
 
 
 
]
 
) had
no effect on cell detachment. Thus, HT-1080 cell detach-
ment by PAI-1 is a uPA-
 
 
 
but not a VN-dependent process.
Figure 2. Effect of PAI-1 on uPA–uPAR– V-integrin complexes. 
HT-1080 cells were acid washed, detached in enzyme-free solution, 
resuspended in serum-free RPMI/0.02% BSA, and incubated for 1 h 
at 4 C in the absence or presence of uPA (as described in Materials 
and methods). The cells were washed again, and PAI-1 or the indicated 
PAI-1 variants were added for 10 min at 18 C. Cell lysates were 
prepared and immunoprecipitated using mAbs against  V 3 (LM609, 
A) or against  V 5 (P1F6, B). The resulting immunoprecipitates were 
fractionated by SDS-PAGE, transferred to PVDF membranes, and 
immunoblotted using pAbs against uPAR. The results were quantified 
by densitometry and are presented as percentage of relative density 
units (RDU) normalized to uPA alone.
Figure 3. Effect of the sequential addition of uPA and PAI-1 on 
the activity state of surface integrins. (A) Reattachment of cells to 
VN40–459. HT-1080 cells were detached from VN either by 
trypsinization (left) or by sequential incubation with uPA and PAI-1 
(right). The cells were washed in RPMI/BSA to remove unbound 
PAI-1 and trypsin and then allowed to reattach to VN40–459-coated 
microtiter plates at 4 C in the presence of uPA alone or uPA plus 
either MnCl2 or MnCl2 plus EDTA. After incubation for 2 h at 4 C, 
the number of reattached cells was determined as described in 
Materials and methods. Each column is expressed as a percentage 
of the control (trypsin-released cells; 100%)   SD. (B) Binding of 
125I-VN to detached cells. Cells were detached by incubation in 
enzyme-free buffer, washed, and incubated with 
125I-labeled VN for 
1 h at 4 C in the presence of uPA alone, uPA plus PAI-1, uPA plus 
PAI-1 plus MnCl2, uPA plus LM609 (anti- V 3), or uPA plus P1F6 
(anti- V 5, 50  g/ml). The amount of bound ligand (ng/mg total 
protein) was calculated as specifically bound cpm (Materials and 
methods) divided by the specific activity of the 
125I-labeled VN.T
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PAI-1 decreases the level of uPAR–
 
 
 
V
 
 integrin 
complexes on the cell surface
 
It is now clear that the binding of uPA to uPAR on the cell
surface leads to the formation of molecular complexes be-
tween the occupied receptor and a variety of integrins and
that these changes promote stronger cell adhesion to VN
(Chapman and Wei, 2001; Kjoller, 2002). Since addition
of PAI-1 to uPA-occupied uPAR leads to cell detachment
from VN (Fig. 1), we hypothesized that the effects of PAI-1
on cell detachment were mediated by decreases in uPAR–
integrin complexes at the cell surface. To test this possibil-
ity, uPA-pretreated cells were incubated with PAI-1 (or the
PAI-1 variants) at 18
 
 
 
C to permit internalization of surface
proteins. Postnuclear supernatants were prepared, immu-
noprecipitated using mAbs against VN-specific integrins,
and then analyzed by immunoblotting for uPAR (Fig. 2).
The addition of uPA caused a fivefold increase in the
amount of uPAR coimmunoprecipitated with antibodies
against 
 
 
 
V
 
 
 
3
 
 (Fig. 2 A). Subsequent addition of PAI-1 re-
duced the amount of immunoprecipitated uPAR to control
values. Similar results were obtained when the immunopre-
cipitation experiments were performed using the mAb
against 
 
 
 
V
 
 
 
5
 
 (Fig. 2 B). Again, addition of the PAI-1 vari-
ant, which did not bind to uPA (i.e., PAI-1
 
[P
 
 
 
V
 
 
 
]
 
), had no
effect on the amount of precipitable uPAR–
 
 
 
V
 
 
 
5
 
 com-
plexes. Together, the data in Fig. 2, A and B, indicate that
PAI-1 decreases the amount of uPA–uPAR–
 
 
 
V
 
 integrins at
the cell surface.
 
Cells released by PAI-1 do not reattach to VN
 
To begin to investigate the mechanism of cell detachment
by PAI-1, HT-1080 cells were detached from VN by treat-
ment with trypsin or by sequential incubation with uPA and
PAI-1 as above. The cells were then washed and allowed to
reattach to VN
 
40–459
 
 (which lacks the uPAR binding do-
main), thus only permitting cell attachment via integrins.
The trypsin-released control cells (i.e., uPA alone) rapidly
and completely reattached to this VN variant (Fig. 3 A).
This reattachment was not enhanced further by the addition
of MnCl
 
2
 
, a treatment known to activate 
 
 
 
V
 
-integrins (Pam-
pori et al., 1999) but was significantly reduced by EDTA.
Thus, adhesion of these trypsinized cells did not require in-
tegrin activation. In contrast to these results, 
 
 
 
10% of the
cells that were detached by sequential treatment with uPA
and PAI-1 were able to reattach to VN
 
40–459
 
 under these
conditions. In this case, the magnitude of reattachment was
dramatically increased by the addition of MnCl
 
2
 
. Thus, se-
quential treatment with uPA and PAI-1 appears to decrease
the number of active integrins on the cell surface.
 
Binding of VN to uPA/PAI-1–treated HT-1080 cells
 
Experiments were performed to test the possibility that
the inability of the uPA/PAI-1–treated cells to reattach to
VN
 
40–459
 
 (Fig. 3 A) reflects the absence of active integrins.
HT-1080 cells were detached nonenzymatically (see Materi-
als and methods) and then incubated with 
 
125
 
I-labeled VN
at 4
 
 
 
C (to prevent internalization of surface proteins) in the
absence or presence of uPA alone or uPA followed by PAI-1.
The 
 
125
 
I-VN bound very efficiently to control cells treated
with uPA alone (Fig. 3 B). However, considerably less bind-
ing was observed when cells pretreated with uPA/PAI-1 were
employed, and this binding was again stimulated by the ad-
dition of MnCl
 
2
 
. Together, these observations suggest that
sequential treatment of HT-1080 cells with uPA and PAI-1
converts the majority of active integrins at the cell surface
into an inactive state. Fig. 3 also shows that antibodies
against 
 
 
 
V
 
 
 
3
 
 and 
 
 
 
V
 
 
 
5
 
 reduced the binding of 
 
125
 
I-VN to
uPA-treated cells by 
 
 
 
40 and 
 
 
 
70%, respectively. LM609
and P1F6 also blocked the attachment of HT-1080 cells to
VN by similar amounts (unpublished data), whereas a non-
specific IgG had no effect. Although the combined effects of
the two antiintegrin antibodies slightly exceeded 100%, this
Figure 4. Effects of uPA and PAI-1 on LRP-mediated endocytosis 
of  V-integrins. (A) HT-1080 cells were acid washed, surface 
biotinylated, and detached from VN by incubation in enzyme-free 
buffer. Suspended cells (10
7, in RPMI/BSA) were then incubated as 
indicated with uPA for 1 h at 4 C followed by incubation (1 h, 18 C) 
in the absence or presence of either PAI-1 or anti-LRP pAb. (B) As 
indicated, cells were incubated sequentially with uPA and PAI-1 in the 
absence or presence of RAP or a nonspecific IgG or were incubated 
with preformed uPA–PAI-1 complexes. Postnuclear supernatants 
were prepared and fractionated by centrifugation, and the individual 
fractions were analyzed for the presence of biotinylated  V-integrins 
or uPAR in the PM or EE containing gradient fractions.T
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effect was within the variation of these experiments. Thus,
these two integrins play a significant role in HT-1080 cell
attachment to VN, and both are regulated by PAI-1. When
considered together with the coimmunoprecipitation data
(Fig. 2), these observations suggest that addition of PAI-1 to
uPA-pretreated cells leads to a deactivation of 
 
 
 
V
 
-integrins
in conjunction with a decrease in precipitable uPAR–
 
 
 
V
 
-inte-
grin complexes at the cell surface.
 
PAI-1 initiates LRP-mediated endocytosis of 
uPA–uPAR–
 
 
 
V
 
-integrin complexes
 
Although incubation of HT-1080 cells with uPA and PAI-1
leads to the formation and internalization of PAI-1–uPA–
uPAR complexes by LRP (Czekay et al., 2001), little infor-
mation is available about the fate of the integrins that also
are associated with these complexes (Fig. 2). To further in-
vestigate this question, HT-1080 cells were surface biotin-
ylated and then detached from VN by incubation in non-
enzymatic cell dissociation solution. The suspended cells
were then incubated with uPA alone at 4
 
 
 
C or with uPA
(4
 
 
 
C) followed by PAI-1 (18
 
 
 
C). Incubation at 4
 
 
 
C prevents
the internalization of surface proteins, whereas incubation at
18
 
 
 
C (Dunn et al., 1989) allows endocytosed proteins to ac-
cumulate in early or sorting endosomes but prevents them
from progressing further down the endocytic pathway (i.e.,
cargo transport to lysosomes for degradation; receptor recy-
cling to the plasma membrane [PM]). Cell lysates were pre-
pared and fractionated on Percoll gradients, and fractions
containing the PMs and early endosomes (EEs) were col-
lected and analyzed for the presence of biotinylated inte-
grins. As indicated in Fig. 4 A, when uPA alone was added
to the cells 
 
 
 
V
 
 
 
3
 
 (panel a) and 
 
 
 
V
 
 
 
5
 
 (panel d) were detected
only in PM fractions. Thus, under these conditions 
 
 
 
V
 
-inte-
grins appear to be localized to the cell surface. Subsequent
addition of PAI-1 induced a significant shift of these inte-
grins into EE fractions (Fig. 4 A, b and e), and anti-LRP an-
tibodies greatly reduced these effects (Fig. 4 A, c and f).
Thus, the PAI-1–mediated internalization of these integrins
occurs via an LRP-dependent mechanism. These observa-
tions support the hypothesis that the binding of PAI-1 to
uPA–uPAR–integrin complexes initiates cell detachment by
deactivating and disengaging uPAR and 
 
 
 
V
 
-integrins and
prevents cell reattachment to VN by initiating the simulta-
neous clearance of the two adhesion receptors.
Additional experiments were performed to determine
whether 
 
 
 
V
 
 
 
5 and uPAR were internalized separately or in
complex with each other. The pooled gradient fractions con-
taining either PM or EE were immunoprecipitated with anti-
bodies against 
 
 
 
V
 
 
 
5 (P1F6) and then analyzed for the presence
of uPAR by immunoblotting after SDS-PAGE. As indicated
in Fig. 4 B, when the cells were incubated sequentially with
uPA and PAI-1 the majority of both  V 5 (panel a), and uPAR
(panel e) were detected in EE. The addition of receptor-associ-
ated protein (RAP) blocked the shift of  V 5 (Fig. 4 B, b) and
uPAR (Fig. 4 B, f) from the PM into EE, whereas the presence
Figure 5. PAI-1 detaches HT-1080 cells from FN and Coll-I. 
HT-1080 cells were seeded onto FN- or Coll-I–coated wells in 
serum-free RPMI/BSA for 1.5 h. The cells were acid washed and 
then incubated with uPA alone, uPA followed by PAI-1, or uPA 
followed by PAI-1(P V ). After incubation, the cultures were washed 
vigorously, and the remaining attached cells were quantitated by 
crystal violet staining. Each column is expressed as a percentage of 
the control ( uPA; 100%)   SD.
Figure 6. PAI-1 detaches CHO cells from VN and FN. CHO-WT 
and CHO cell clones overexpressing either  V 3 or uPAR were 
allowed to attach to VN- (A) or FN- (B) coated wells by incubation 
in serum-free medium for 1.5 h. The attached cells were acid washed 
and then incubated with uPA alone, PAI-1 alone, or uPA followed by 
PAI-1. After incubation, the remaining attached cells were quantitated 
by crystal violet staining. Each column is expressed as a percentage 
of the control (CHO-WT in  uPA; 100%)   SD.T
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of a nonspecific IgG had no effect (Fig. 4 B, c and g). Thus,
the sequential addition of uPA and PAI-1 appears to internal-
ize  V-integrins in complex with uPAR. If the cells were incu-
bated with preformed uPA–PAI-1 complexes (instead of se-
quential incubation with uPA and PAI-1), the amount of  V 5
(Fig. 4 B, d) in EE was significantly reduced. However, our
earlier studies (Czekay et al., 2001) showed that under these
conditions uPAR is internalized into EE.
Detachment of HT-1080 cells from FN and type-1 
collagen by PAI-1
The effects of PAI-1 on cell detachment are VN indepen-
dent, raising the possibility that the inhibitor can also detach
cells from other matrix proteins which do not contain bind-
ing sites for PAI-1 and/or uPAR. This hypothesis is sup-
ported by the observation that the sequential addition of
uPA and PAI-1 (or PAI-1[P V ])) to HT-1080 cells attached
to FN or type-1 collagen (Coll-I) detached  35–40% of the
cells (Fig. 5).
Comparison of Figs. 1 and 5 indicates that the sequential
addition of uPA and PAI-1 induced significantly less cell
detachment from FN and Coll-I than from VN. Although
FN and Coll-I contain multiple binding sites for integrins,
there is only one binding site (i.e., RGD sequence) present
in VN (Okumura et al., 2002). Thus, it is likely that the en-
gagement of a larger number of integrins by cells attached
to FN and Coll-I (versus VN) may lead to stronger adhe-
sion and less effective detachment by PAI-1. In this regard,
there are no published reports showing a direct effect of
PAI-1 on integrins. Figs. 1–4 show that PAI-1 alone has no
effect on free integrins, i.e., it only internalizes those inte-
grins associated with uPA–uPAR complexes. Thus, it may
be the ratio of matrix-engaged uPA–uPAR–integrin com-
plexes to total engaged integrins that determines the effi-
ciency of PAI-1–induced cell detachment. If this hypothesis
is correct, then increasing the amount of surface uPAR
should increase the proportion of active integrins in com-
plex with uPAR and lead to more pronounced cell detach-
ment by PAI-1. To test this hypothesis, wild-type (WT)
CHO cells, which express endogenous  V 3 (Zaffran et al.,
2000) and uPAR (Fowler et al., 1998), and two CHO cell
clones, which overexpress either human  V 3 (Pampori et
al., 1999) or human uPAR (Tarui et al., 2001), were al-
lowed to attach to VN (Fig. 6 A) and FN (Fig. 6 B). These
cells were especially appropriate for these studies since the
 V 3-overexpressing cells produce  40–50  more  V 3
integrin than their WT counterparts (Pampori et al., 1999),
whereas the CHO-uPAR cells express 65–70-fold more
uPAR than the CHO-WT cells ( 47,000 sites/cell versus
 700 sites/cell; unpublished data).
As expected, neither uPA nor PAI-1 alone detached CHO-
WT cells or CHO cells that overexpress  V 3 from VN (Fig. 6
A). However, upon sequential incubation of CHO-WT cells
with uPA and PAI-1 nearly 50% of the cells were detached.
Importantly, this detachment was not observed in the CHO
cells that overexpressed  V 3 integrins. Thus, increasing the ra-
tio of  V 3 to uPAR seemed to inhibit PAI-1–mediated cell
detachment from VN. In parallel experiments, CHO-WT
cells and CHO cells overexpressing human uPAR were al-
lowed to attach to FN (Fig. 6 B). Again, neither uPA nor
PAI-1 alone could detach the cells. In this case, the CHO-WT
cells could not be detached from FN by sequential incubation
with uPA and PAI-1. However, if the CHO cells were overex-
pressing uPAR,  50% of the cells were detached. Thus, in-
creasing the ratio of uPAR over active  V-integrins facilitates
PAI-1–mediated detachment of CHO cells. Together, these
results suggest that the efficiency of cell detachment by PAI-1
depends largely on the fraction of the total matrix-engaged in-
tegrin pool that is actually bound to uPA–uPAR complexes
and can in turn bind PAI-1.
Figure 7. Effect of soluble uPAR on PAI-1 induced cell detachment. 
HT-1080 cells were seeded onto FN- or Coll-I–coated wells and 
processed as described (see legend to Fig. 5). The cells were then 
incubated with uPA alone (lanes 1 and 6), uPA followed by PAI-1 
(lane 2), uPA and suPAR (lanes 3 and 7), or uPA and increasing 
amounts of suPAR (1 or 5  g/ml, lanes 4–5) followed by PAI-1 
(lanes 4, 5, and 8). After incubation, the cultures were washed 
vigorously, and the remaining attached cells were quantitated by 
crystal violet staining. Each column is expressed as a percentage of 
the control ( uPA; 100%)   SD.
Table I. Detachment of various cell lines from VN and FN by PAI-1
Treatment of cells attached to vitronectin Treatment of cells attached to fibronectin
Cell type Control (uPA) uPA   PAI-1 uPA   suPAR   PAI-1 Control (uPA) uPA   PAI-1 uPA   suPAR   PAI-1
HT-1080 100   3.1 31.4   0.2 6.4   1.6 100   3.7 54.2   2.8 17.9   4.2
MCF-7 100   1.6 94.9   1.5 38.9   3.3 100   2.9 78.7   0.7 30.6   8.3
HeLa 100   1.7 49.1   8.9 29.9   1.3 100   2.0 91.3   3.1 36.1   1.3
AoSMC 100   2.7 80.2   4.4 28.6   5.8 100   1.9 102.6   1.8 39.9   0.9
HT-1080, MCF-7, HeLa, and AoSMCs were allowed to attach to VN or FN for 1.5 h at 37°C and then were incubated with uPA alone, or with uPA or uPA–
suPAR followed by PAI-1 as described in Materials and methods. After incubation, the cells were vigorously agitated, and the floating cells were removed
by washing. The relative number of attached cells was quantitated by crystal violet staining (as described in Materials and methods). Each column reflects
the average of triplet samples   SD and is expressed as a percentage of the control (media   uPA, 100%).T
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Effect of soluble uPAR on PAI-1–mediated cell 
detachment from FN, Coll-I, and VN
Experiments were performed to further test the hypothesis
that an excess of uPAR over integrins is necessary for effi-
cient cell detachment by PAI-1. HT-1080 cells attached to
FN or Coll-I were incubated with either uPA alone or with
uPA in the presence of increasing amounts of soluble uPAR
(suPAR) at 4 C. This soluble uPAR was able to bind to uPA
and form complexes with purified  V-integrins and with in-
tegrins at the surface of HT-1080 cells (unpublished data).
Addition of uPA–suPAR alone had no effect on cell detach-
ment from either FN (Fig. 7, lane 3) or Coll-I (Fig. 7, lane
7) compared with controls (uPA alone, Fig. 7, lanes 1 and
6). However, subsequent addition of PAI-1 to the uPA–
suPAR-pretreated cells released  80% of cells from these
matrices (Fig. 7, lanes 5 and 8). These effects of PAI-1 on
cell detachment increased with the concentration of suPAR
employed (Fig. 7, lane 4 compared with 5) and were signifi-
cantly stronger than the effects observed if only endogenous
uPAR was present (Fig. 7, lane 2 compared with 5). The ad-
dition of suPAR to a variety of cells seeded onto VN or FN
matrices also increased the number of cells detached by se-
quential incubation with uPA and PAI-1 (Table I). These
observations indicate that increasing the surface pool of
uPAR leads to more efficient cell detachment by PAI-1.
Discussion
Cell migration is a critical component of many normal and
pathological processes including wound healing and cancer,
and it is clear that regulated changes in the affinity state of
adhesion receptors (e.g., integrins and uPAR) are essential
for optimal cell motility (Lauffenburger and Horwitz, 1996).
It is also clear that this process is influenced by PAI-1 (De-
gryse et al., 2001; Stefansson et al., 2001). The movement of
cells appears to involve at least three interdependent func-
tional events, including (1) attachment of the leading edge of
the cell, (2) cell contraction, and finally (3) detachment of
the trailing edge (Huttenlocher et al., 1995). Although con-
siderable information is available about cell attachment and
contraction, relatively little is known about mechanisms of
cell detachment. What is clear is that several extracellular
proteins can reverse the cell adhesion process by promot-
ing deadhesion events (Murphy-Ullrich, 2001). These pro-
teins, including thrombospondin, tenasin, and osteonectin
(SPARK), can disrupt the link between the cytoskeleton and
the focal adhesion plaque, resulting in the loss of stress fibers
and a decrease in the strength of integrin–ligand interac-
tions. The signals that initiate these events remain to be de-
termined. The experiments in this report not only demon-
strate that PAI-1 should be added to this growing list of
deadhesion molecules but also provide insights into underly-
ing mechanisms. These experiments were initiated to specifi-
cally investigate the influence of PAI-1 on the detachment of
HT-1080 cells from extracellular matrices composed of VN.
However, it soon became apparent that this inhibitor also
can promote the detachment of a variety of cells growing on
different extracellular matrices.
Cells adhere to VN by engaging uPAR, integrins, or both
(Chapman and Wei, 2001; Deng et al., 2001). These adhe-
sive events are initiated in part by the binding of uPA to
uPAR and can be prevented by PAI-1 binding to SMB
(Chapman and Wei, 2001; Deng et al., 2001). Interestingly,
these effects of PAI-1 seem to be specific for VN since the
inhibitor does not bind to FN or other matrix proteins, and
it does not block integrin-mediated cell adhesion to matrices
composed of these molecules (Loskutoff et al., 1999). Based
on these observations, we hypothesized (Deng et al., 2001)
that PAI-1 also can detach cells from VN by binding to
SMB and displacing uPAR and integrins. It is now clear that
the story is much more complex than this and that PAI-1
can detach cells by two separate but related mechanisms, de-
pending on the nature and quantity of the adhesion recep-
tors actually engaged by the attached cells. In the case where
cells bind to VN through uPAR alone (e.g., U937 cells) and
integrins are not engaged, PAI-1 detaches the cells by di-
rectly competing with uPAR for the binding site in the SMB
domain (Deng et al., 2001). Since neither PAI-1 nor uPAR
bind to other matrix proteins, this mechanism of competi-
tive displacement is specific for cells growing on VN and
will not affect cells growing on FN or Coll-I. In the case
where cells adhere to VN either through integrins alone or
through integrins and uPAR (i.e., most other cells), this dis-
placement of uPAR by PAI-1 is not sufficient to detach the
cells, since they remain firmly anchored via integrins (Deng
et al., 2001). Thus, the integrin–VN interaction also has to
be disrupted to release the cells, and this reversal of integrin-
mediated cell adhesion by PAI-1 does not appear to require
VN. This conclusion is supported by several observations.
For example, PAI-1 can detach cells from matrices that do
not contain VN (e.g., matrices composed of FN or Coll-I
[Figs. 5–7 and Table I]). In addition, the PAI-1 variant that
does not bind to VN (i.e., PAI-1[P V ]) efficiently detaches
cells from VN (Figs. 1, 2, and 5). Finally, PAI-1 can detach
cells from a variant of VN that lacks the PAI-1 binding do-
main (i.e., VN40–459 [Fig. 1 B]).
The mechanism by which PAI-1 disrupts integrin-medi-
ated cell attachment was investigated in detail. The fact that
the PAI-1 variant that bound uPA but not VN retained full
detachment activity (Figs. 1, 2, and 5), whereas the variant
that bound VN but not uPA was inactive (Figs. 1 and 2) in-
dicates that the presence of active uPA on the cell surface is
critical for the deadhesive effects of PAI-1. This conclusion
is supported by the observation that the ATF of uPA does
not support cell detachment by PAI-1 (Fig. 1 A). This frag-
ment of uPA binds to uPAR but lacks the binding site for
PAI-1 (Cubellis et al., 1989).
Fig. 2 shows that the interaction of uPA with uPAR pro-
motes complex formation between the occupied receptor
and  V-integrins and that subsequent addition of PAI-1 de-
creases the number of these complexes. This decrease ap-
pears to result from the PAI-1–mediated disengagement of
uPAR–integrin complexes from the extracellular matrix,
leading to the cointernalization of these complexes into EEs
(Fig. 4). This endocytosis requires LRP since anti-LRP anti-
bodies and RAP block this internalization. This is the first
report to our knowledge that PAI-1 can initiate disengage-
ment of integrins from the extracellular matrix and can pro-
mote their endocytic clearance. Interestingly, when the cells
were incubated with preformed uPA–PAI-1 complexes, theT
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amount of  V 5 in EEs was noticeably reduced (Fig. 4 B, d).
However, this treatment is known to promote LRP-medi-
ated internalization of surface uPAR into EEs (Czekay et al.,
2001). Thus, addition of preformed complexes to cells pro-
motes uPAR internalization via LRP but does not promote
uPAR binding to integrins or integrin internalization. The
addition of active uPA to cells is required to initiate uPAR–
integrin interactions (Fig. 2) (Wei et al., 2001). The obser-
vations in Fig. 4 suggest that the binding of PAI-1 to the
uPA-primed cells is a prerequisite for the endocytic clearance
of integrins by LRP (see model in Fig. 8). According to this
hypothesis, PAI-1 would only affect those integrins which
are present in complex with uPA and uPAR. It would not af-
fect free integrins (i.e., those not associated with uPA–PAR
complexes). Based on these observations, we propose that
the binding of PAI-1 to uPA in complex with uPAR triggers
internalization and presumably recycling of integrins, LRP,
and uPAR (Nykjær et al., 1997) to the cell surface.
The endocytic clearance of uPAR and integrins can only
occur after their disengagement from VN. Therefore, we ad-
dressed the question of whether the binding of PAI-1 to
uPA–uPAR–integrin complexes leads to deactivation of the
integrins before their internalization. This appears to be the
case, since sequential treatment of cells with uPA and PAI-1
at 4 C also decreased VN binding (Fig. 3 B). Incubation of
cells at this temperature prevents endocytosis and keeps
uPAR and integrins at the cell surface. Thus, the binding of
PAI-1 to uPA seems to initiate the rapid and specific inacti-
vation of the  V-integrins present in uPA–uPAR–integrin
complexes before the disengagement of these complexes
from the matrix and their endocytosis by LRP. This simulta-
neous clearance of the two cell adhesion receptors promotes
the subsequent detachment of HT-1080 cells from VN. Fig.
8 also emphasizes that uPAR is the surface receptor which
transmits the effects of PAI-1 to integrins. Since the attach-
ment of cells to a specific matrix is determined by the pres-
ence of specific cell surface integrins and since PAI-1 de-
taches cells from a variety of matrices (Table I), we must
conclude that uPAR can somewhat indiscriminately trans-
mit the effects of PAI-1 to the specific integrins involved in
the adhesive event. This conclusion is supported by observa-
tions showing that uPAR can associate with a variety of inte-
grins at the cell surface (Chapman and Wei, 2001).
Importantly, the uPA–uPAR-dependent mechanism of
cell detachment is not unique to HT-1080 cells growing on
VN. In fact, PAI-1 can also detach CHO, MCF-7, HeLa,
and aortic smooth muscle cells (AoSMCs) from VN, FN,
and Coll-I by a similar mechanism (Figs. 5–7 and Table I).
Interestingly, the ability of PAI-1 to detach cells varies with
the composition of the matrix (Figs. 1, 5, and 6 and Table
I). This variation is probably related to differences in the
number of integrin binding sites in each matrix. For exam-
ple, the variation observed between VN, FN, and Coll-I
may reflect the fact that FN and Coll-I contain more bind-
ing sites for integrins than VN. It is likely that a larger por-
tion of the surface integrin pool can engage these adhesive
glycoproteins, thus leading to stronger cell adhesion.
The ability of PAI-1 to detach cells also varies consider-
ably from cell type to cell type (Figs. 1 and 6 and Table I),
and we speculate that this variation is due to large differ-
ences in the expression of surface uPAR (Deng et al., 2001).
More specifically, we hypothesize that it is the ratio of cell
surface uPAR to the total pool of engaged integrins that de-
termines the number of uPAR–integrin complexes that can
Figure 8. Model depicting proposed 
events in PAI-1 induced cell detachment. 
(Step 1) Cells attach to their preferred 
extracellular matrix proteins via integrins; 
unoccupied uPAR and LRP are available 
at the cell surface. (Step 2) uPA released 
from cells binds to surface uPAR initiating 
complex formation between the now 
occupied uPAR and integrins. If the matrix 
contains VN, the uPA–uPAR complexes 
will bind to it, strengthening cell adhesion. 
(Step 3) PAI-1 released from cells binds 
to the uPA–uPAR–integrin complexes, 
leading to their deactivation and 
subsequent dissociation from the matrix 
and cell detachment. The presence of 
PAI-1 also mediates the binding of these 
complexes to LRP, their redistribution 
into clathrin-coated pits (Step 4), and 
their LRP-mediated endocytosis into EEs 
(Step 5). The uPA–PAI-1complexes 
dissociate from uPAR and LRP and (Step 6) 
traffic through late endosomes (LE) to 
lysosomes for degradation. (Step 7) The 
unoccupied LRP–uPAR–integrin 
complexes also dissociate, and (Step 8) 
return to the cell surface via recycling 
vesicles (RV). This last step makes uPAR 
and integrins available at the cell surface 
for reattachment to the matrix.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 Cell detachment by PAI-1 | Loskutoff et al. 789
be affected (i.e., deactivated) by PAI-1. According to this
idea, an increase in cell surface uPAR over total engaged in-
tegrins would enhance the deadhesive effects of PAI-1. This
hypothesis is supported by the observation that overexpres-
sion of uPAR in CHO cells (i.e., increased ratio of uPAR to
integrins) led to a pronounced increase in the efficiency of
PAI-1 to detach the cells from FN (Fig. 6 B). However,
when the surface pool of  V 3 integrins was enlarged to de-
crease this ratio (i.e., in CHO cells overexpressing  V 3 [Fig.
6 A]), PAI-1 treatments failed to detach the cells, especially
from VN. Based on these observations, we hypothesized that
cell surface uPAR might be limiting in some cells and that
incubation of these cells with soluble uPAR in the presence
of uPA would promote complex formation with a larger por-
tion of the total active integrins. This change would again al-
low PAI-1 to associate with and inactivate a higher pro-
portion of the total engaged integrin pool, increasing its
efficiency of cell detachment. This hypothesis is supported
by the observation that when HT-1080 cells were incubated
with soluble uPAR in the presence of uPA, a dose-depen-
dent increase in the amount of cells detached from FN and
Coll-I by PAI-1 was observed (Fig. 7). Additional tests dem-
onstrated that in the presence of uPA, soluble uPAR was
able to form immunoprecipitable complexes with purified
 V-integrins (unpublished data; Wei et al., 2001). The addi-
tion of soluble uPAR (in the presence of uPA) also enhanced
PAI-1–mediated detachment of HT-1080, MCF-7, HeLa,
and AoSMC cells from VN and FN (Table I).
In summary, when cells bind to VN via uPAR and inte-
grins (e.g., HT-1080 cells [Deng et al., 2001]) and the
uPAR to integrin ratio is high PAI-1 detaches the cells via a
uPA-dependent mechanism that leads to deactivation and
disengagement of uPAR and integrins (Fig. 8). When cells
bind to other matrix proteins (i.e., FN and Coll-I) through
integrins alone, PAI-1 can detach them by the same uPA-
dependent and uPAR-mediated mechanism as long as the
ratio of the engaged uPA–uPAR–integrin complexes to the
total pool of engaged integrins is high. In cells where the sur-
face pool of active integrins exceeds the uPAR pool (i.e.,
MCF-7 [Deng et al., 2001]), PAI-1 cannot detach cells from
VN. Thus, if integrin-mediated adhesion is not accompa-
nied by sufficient surface expression of uPAR, PAI-1 will be
unable to detach the cells.
It is tempting to speculate that the deadhesive effects of
PAI-1 are related to the observation that high PAI-1 levels
are associated with a poor prognosis for survival in several
metastatic human cancers (Andreasen et al., 2000; Foekens
et al., 2000). In fact, the prognostic relevance of high tumor
expression of PAI-1, as well as uPA and uPAR, for cancer in-
vasiveness, metastatic spreading, and poor relapse-free sur-
vival is now well established. Moreover, recent reports indi-
cate that high plasma levels of soluble uPAR are associated
with a continuously increasing risk of mortality in breast
cancer (de Witte et al., 2001). PAI-1–induced cell detach-
ment is enhanced by the presence of soluble uPAR (Fig. 7
and Table I). Thus, Fig. 8 also emphasizes the central role of
uPAR as a transmitter of the deadhesive effects of PAI-1
through the rapid redistribution and reutilization of adhe-
sion receptors at the leading edge of these cells. Thus, we can
envision an in vivo scenario where tumor-derived uPA and
soluble uPAR will form complexes which bind to integrins
on the cancer cells, thus facilitating the deadhesive effects of
PAI-1 produced by the tumor and/or stromal cells. This ef-
fect might then enhance the dissemination of these cells
from the tumor. This hypothesis remains to be tested.
Materials and methods
Reagents
Protein G–agarose, heparin sepharose, and Percoll were from Amersham
Biosciences, RGD peptide (GRGDSP) was from Peninsula Laboratories,
and Biotin-XX was purchased from Molecular Probes. Na-
125I was pur-
chased from PerkinElmer, Iodo beads and the ECL detection system were
from Pierce Chemical Co., and the ABC kit for detecting biotinylated pro-
teins was from Vector Laboratories. FBS was from HyClone, RPMI and
DME cell culture media and trypsin/EDTA cell dissociation solution were
from Invitrogen, and nonenzymatic cell dissociation solution and CHAPS
were from Sigma-Aldrich. All other chemicals and buffers were of the
highest analytical grade available.
Proteins
uPA, ATF, and uPAR. Active two-chain uPA (human) was purchased from
American Diagnostica. The ATF (residues 1–135) of human uPA was a gift
from Dr. Michael Ploug (Finsen Laboratory, Copenhagen, Denmark), and
soluble human uPAR (Tarui et al., 2001) was supplied by Dr. Douglas
Cines (University of Pennsylvania, Philadelphia, PA).
RAP. RAP was provided by Dr. J.G. Neels from our laboratory. It was ex-
pressed and purified as a GST fusion protein (Herz et al., 1991).
PAI-1. The recombinant stable active form of PAI-1 (14–1b [Berkenpas
et al., 1995]) was a gift from Dr. Dan Lawrence (American Red Cross,
Rockville, MD) and is referred to throughout this article as PAI-1. Two re-
combinant PAI-1 mutants were constructed on this 14–1b background
by performing oligonucleotide-directed site-specific mutagenesis (Quick-
Change Site-Directed Mutagenesis kit; Stratagene). The first mutation,
Q123→K, generated a PAI-1 variant with no detectable affinity for VN but
with normal inhibitory activity against PAs (Lawrence et al., 1994). This
mutant is referred to as PAI-1[P V ]. The second variant contained two mu-
tations (T333→R and A335→R) which resulted in the loss of the PA inhib-
itory activity of PAI-1 but did not affect its binding affinity for VN (Stefans-
son et al., 2001). This mutant is referred to as PAI-1[P V ]. All PAI-1 variants
were expressed in Escherichia coli strain BL21[DE3]pLysS (Stratagene), and
their sequences were confirmed by DNA sequencing. Protein expression
was induced by incubating the bacteria with 0.2 mM IPTG for 4–5 h at
30 C. The resulting PAI-1 variants were purified (Kvassman and Shore,
1995) and tested both for their affinity for PAs (Strandberg and Madison,
1995) and for VN (Okumura et al., 2002). Protein concentrations were de-
termined by the BCA method (Pierce Chemical Co.).
Extracellular matrix proteins. Multimeric VN was purified from human
plasma as described (Yatohgo et al., 1988). A truncated form of VN repre-
senting aa residues 40–459 (i.e., VN40–459) was constructed from the human
VN cDNA (Okumura et al., 2002). This VN variant lacks the binding sites
for uPAR and PAI-1 but still contains the RGD sequence for integrin bind-
ing. Human FN and human Coll-I were obtained from Becton Dickinson.
Antibodies. mAbs against human  V 3 (LM609) and  V 5 (P1F6) inte-
grins were purchased from Chemicon International. Rabbit polyclonal an-
tibodies (pAbs) against recombinant soluble human uPAR1–274 and human
LRP, and a mAb (11H4), which recognizes the cytoplasmic tail of LRP,
were supplied by Dr. M. Farquhar (University of California at San Diego,
San Diego, CA). HRP-coupled donkey anti–rabbit and anti–mouse (H   L)
IgG, depleted of cross-reactivity, were purchased from Jackson Immu-
noResearch Laboratories.
Cell culture
WT CHO-K1 cells and CHO-K1 cells overexpressing either human  V 3 or
human uPAR were supplied by Drs. S. Shattil (Pampori et al., 1999) and Y.
Takada (Tarui et al., 2001), respectively, from The Scripps Research Insti-
tute. A human AoSMC line and the recommended culture medium
(SmGM-2) were purchased from BioWhittaker. All other cell lines were
purchased from American Type Culture Collection and were cultured in
DME supplemented with 10% FBS.
Acid treatment of cells
Unless otherwise indicated, cultured cells were acid treated (Cubellis et
al., 1989; Czekay et al., 2001) before incubation with exogenously addedT
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uPA or PAI-1. Briefly, the cells were incubated in glycine buffer at pH 4.0
for 3 min at 4 C and then neutralized by incubation in TRIS buffer at pH
7.4 for 10 min. The acid-treated cells responded in a similar but more dra-
matic manner compared with control cells which were not acid washed or
incubated at 4 C before addition of uPA and PAI-1.
Cell detachment assay
To perform cell detachment experiments, microtiter plates were coated
with various extracellular matrix proteins including VN (5  g/ml), VN40–459
(20  g/ml), FN (5  g/ml), or type I collagen (5  g/ml) for 18 h at 4 C. Cells
(1.5   10
5) in RPMI containing 0.02% BSA (RPMI/BSA) were added to each
well and allowed to attach for 1.5 h at 37 C. The monolayers were then
acid treated as above, washed twice in ice-cold RPMI/BSA, and then incu-
bated in the absence or presence of uPA (50 nM) or ATF (50 nM) for 1 h at
4 C. Unbound uPA and ATF were removed by additional washing in RPMI/
BSA at 4 C, and then either PAI-1, PAI-1[P V ], or PAI-1[P V ] (all at 40  g/
ml) was added to the cells for 30 min at 4 C in RPMI/BSA. In some cases,
soluble uPAR (suPAR, 1 and 5  g/ml) was added together with uPA,
whereas in other experiments RGD peptide (500  g/ml) was added together
with PAI-1[P V ]. After incubation for 5 min at 37 C in prewarmed RPMI/
BSA, the microtiter plates were agitated twice for 2 min (Molecular Devices
Vmax Plate Reader) and gently washed with RPMI. The remaining adherent
cells were fixed (100% methanol), stained (0.1% crystal violet), and washed
in water. The stain was extracted from the cells with 10% acetic acid, and
the amount of extracted stain was quantitated by absorbance at 590 nm.
Cell reattachment assay
HT-1080 cells were grown on VN-coated microtiter plates and detached
either by sequential incubation with uPA and PAI-1 as described above or
by using trypsin. The detached cells were collected by centrifugation (180 g,
5 min, 4 C) and washed twice in 10 ml of ice-cold RPMI/BSA to remove
trypsin and unbound PAI-1. The washed cells were resuspended in RPMI/
BSA (4 C) and then added to microtiter plates coated with VN40–459 in the
absence or presence of either MnCl2 (2 mM) alone or MnCl2 containing
EDTA (5 mM). The cells were allowed to reattach by incubation for 2 h at
4 C, and then the plates were agitated and washed to remove nonadherent
cells. The remaining adherent cells were quantitated as described above.
Binding of radioiodinated VN to the cell surface
VN was radioiodinated with Na-
125I to a specific activity of 7,145 cpm/ng
using Iodo beads. Attached HT-1080 cells were acid stripped as described
above and then were washed twice in PBS at 4 C and detached in en-
zyme-free cell detachment solution. The detached cells were collected,
washed, resuspended in RPMI/BSA and then were incubated in RPMI/BSA
with 
125I-labeled VN (50 nM) at 4 C for 1 h in the presence of either uPA
alone (50 nM) or uPA followed by incubation with PAI-1 (40  g/ml) in the
absence or presence of MnCl2 (2 mM). In some experiments, cells were in-
cubated with uPA in the presence of mAbs against  V 3 (LM609, 50  g/ml)
or  V 5 (P1F6, 50  g/ml). Each of these experiments also was performed in
the presence of a 60-fold excess of unlabeled VN (3  M). Cell surface-
bound radioactivity was detected by gamma counting. Specificity of 
125I-
VN binding was defined as the difference between total binding (without
competition) and nonspecific binding (i.e., binding that was not competed
with the unlabeled VN). The amount of bound ligand was defined as total
specific cpm divided by the specific activity of 
125I-labeled VN and nor-
malized to total cell protein.
Cell surface biotinylation
After acid stripping the cells as described above, cell surface proteins were
biotinylated using Biotin-XX as described previously (Czekay et al., 2001).
Immunoprecipitation and immunoblotting
For immunoprecipitation, cell lysates were prepared in 10 mM CHAPS in
buffer HB (20 mM Hepes, pH 7.4, 150 mM NaCl, 2 mM CaCl2). The cell
lysates were then incubated for 18 h at 4 C in the presence of protein
G–agarose beads and mAbs against either  V 3 (LM609) or  V 5 (P1F6).
The beads were washed, extracted into reducing sample buffer, and the
extracts were fractionated by SDS-PAGE and analyzed by immunoblotting
with anti-uPAR pAb as described previously (Czekay et al., 2001). Biotin-
ylated proteins were detected using the ABC kit followed by ECL.
Internalization of  V-integrins and cell fractionation
Acid-washed and surface-biotinylated HT-1080 cells were detached in en-
zyme-free cell detachment solution. The resuspended cells were either in-
cubated with uPA (50 nM) for 1 h at 4 C, washed with RPMI, and then in-
cubated in RPMI/BSA in the absence or presence of PAI-1 (40  g/ml) for
1 h at 18 C, or were incubated for 1 h at 4 C followed by 1 h at 18 C in the
presence of preformed uPA–PAI-1 complexes (Cubellis et al., 1989). Cell
fractionation was performed at 4 C using 20% Percoll as described previ-
ously (Czekay et al., 2001). Gradient fractions containing PM-derived ma-
terial or early endosomal material were pooled and then analyzed for the
presence of biotinylated  V 3 and  V 5 by immunoprecipitation with mAbs
LM609 (against  V 3) and P1F6 (against  V 5), respectively, and blotting
with HRP-coupled avidin followed by ECL. Some immunoprecipitates
(P1F6) were also analyzed for the presence of uPAR by immunoblotting
with anti-uPAR pAb followed by ECL. In some cases, binding and internal-
ization experiments were performed in the presence of protein A–purified
nonspecific IgG or anti-LRP IgG (both at 200  g/ml), or RAP (10  g/ml).
Statistical analysis
In general, all experiments were performed three times. Quantitative re-
sults are presented as the average of the three experiments, each per-
formed in triplicate,   SD.
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